We firstly constructed an independent cohort composed of 60 GC patients receiving either DOS (N = 20: DSG, N = 10; DNSG, N = 10), XELOX (N = 20: XSG, N = 10; XNSG, N = 10), or anti-HER2 (N = 20: HSG, N = 10; HNSG, N = 10) therapies (Supplementary Data 3). This evidence concerns the gene ERBB2 and gastric cancer.